Mehmood Yasir, Shahid Hira, Barkat Kashif, Ibraheem Muhammad, Riaz Humayun, Badshah Syed Faisal, Chopra Hitesh, Sharma Rohit, Nepovimova Eugenie, Kuca Kamil, Valis Martin, Emran Talha Bin
Riphah Institute of Pharmaceutical Sciences (RIPS), Riphah International University Faisalabad, Faisalabad, Pakistan.
Saffron Pharmaceuticals (Pvt.) Ltd., Faisalabad, Pakistan.
Front Cell Dev Biol. 2023 Jan 6;10:1026477. doi: 10.3389/fcell.2022.1026477. eCollection 2022.
The main objective of the current research work was to synthesize mesoporous silica nanoparticles for controlled delivery of mometasone furoate for potential nasal delivery. The optimized sol-gel method was used for the synthesis of mesoporous silica nanoparticles. Synthesized nanoparticles were processed through Zeta sizer, SEM, TEM, FTIR, TGA, DSC, XRD, and BET analysis for structural characterization. The dissolution test was performed for the inclusion compound, while the Franz diffusion experiment was performed for permeability of formulation. For the determination of expression levels of anti-inflammatory cytokines IL-4 and IL-5, RNA extraction, reverse transcription, and polymerase chain reaction (RT-PCR) were performed. The MTT assay was also performed to determine cell viability. Synthesized and functionalized mesoporous silica nanoparticles showed controlled release of drugs. FT-IR spectroscopy confirmed the presence of the corresponding functional groups of drugs within mesoporous silica nanoparticles. Zeta sizer and thermal analysis confirmed the delivery system was in nano size and thermally stable. Moreover, a highly porous system was observed during SEM and TEM evaluation, and further it was confirmed by BET analysis. Greater cellular uptake with improved permeability characteristics was also observed. As compared to the crystalline drug, a significant improvement in the dissolution rate was observed. It was concluded that stable mesoporous silica nanoparticles with significant porosity were synthesized, efficiently delivering the loaded drug without any toxic effect.
当前研究工作的主要目标是合成介孔二氧化硅纳米颗粒,用于糠酸莫米松的控释,以实现潜在的鼻腔给药。采用优化的溶胶-凝胶法合成介孔二氧化硅纳米颗粒。通过Zeta粒度分析仪、扫描电子显微镜(SEM)、透射电子显微镜(TEM)、傅里叶变换红外光谱(FTIR)、热重分析(TGA)、差示扫描量热法(DSC)、X射线衍射(XRD)和比表面积分析(BET)对合成的纳米颗粒进行结构表征。对包合物进行溶出试验,对制剂的渗透性进行Franz扩散实验。为了测定抗炎细胞因子IL-4和IL-5的表达水平,进行了RNA提取、逆转录和聚合酶链反应(RT-PCR)。还进行了MTT试验以测定细胞活力。合成并功能化的介孔二氧化硅纳米颗粒显示出药物的控释。傅里叶变换红外光谱证实了介孔二氧化硅纳米颗粒中存在相应的药物官能团。Zeta粒度分析仪和热分析证实了给药系统呈纳米尺寸且热稳定。此外,在扫描电子显微镜和透射电子显微镜评估中观察到高度多孔的系统,并通过比表面积分析进一步证实。还观察到细胞摄取增加,渗透性特征得到改善。与结晶药物相比,溶出速率有显著提高。得出的结论是,合成了具有显著孔隙率的稳定介孔二氧化硅纳米颗粒,能够有效递送负载的药物且无任何毒性作用。